[{"id":"MU12284971","type":"single base substitution","chromosome":"13","start":28610183,"end":28610183,"mutation":"A>G","assemblyVersion":"GRCh37","referenceGenomeAllele":"A","testedDonorCount":978,"affectedDonorCountTotal":9,"affectedDonorCountFiltered":9,"affectedProjectCount":4,"consequences":[{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"splice_region_variant","transcriptsAffected":[{"name":"FLT3-001","id":"ENST00000241453"},{"name":"FLT3-201","id":"ENST00000380982"},{"name":"FLT3-002","id":"ENST00000380987"},{"name":"FLT3-202","id":"ENST00000537084"}],"functionalImpact":"Unknown"}],"study":[],"external_db_ids":{"clinvar":null,"civic":null},"clinical_significance":{"clinvar":null},"clinical_evidence":{"civic":null},"advQuery":{"mutation":{"id":{"is":["MU12284971"]}}},"uiDonors":[{"term":"BRCA-KR","count":1,"advQuery":{"mutation":{"id":{"is":["MU12284971"]}},"donor":{"projectId":{"is":["BRCA-KR"]}}},"countTotal":50,"percentage":0.02,"projectName":"Breast Cancer - Very young women"},{"term":"COCA-CN","count":5,"advQuery":{"mutation":{"id":{"is":["MU12284971"]}},"donor":{"projectId":{"is":["COCA-CN"]}}},"countTotal":321,"percentage":0.01557632398753894,"projectName":"Colorectal Cancer - CN"},{"term":"LAML-KR","count":2,"advQuery":{"mutation":{"id":{"is":["MU12284971"]}},"donor":{"projectId":{"is":["LAML-KR"]}}},"countTotal":205,"percentage":0.00975609756097561,"projectName":"Acute Myeloid Leukemia - KR"},{"term":"LICA-CN","count":1,"advQuery":{"mutation":{"id":{"is":["MU12284971"]}},"donor":{"projectId":{"is":["LICA-CN"]}}},"countTotal":402,"percentage":0.0024875621890547263,"projectName":"Liver Cancer - CN"}]},{"id":"MU90171725","type":"insertion of <=200bp","chromosome":"13","start":28642206,"end":28642206,"mutation":"->TTTTTTGTTT","assemblyVersion":"GRCh37","referenceGenomeAllele":"-","testedDonorCount":67,"affectedDonorCountTotal":9,"affectedDonorCountFiltered":9,"affectedProjectCount":1,"consequences":[{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"intron_variant","transcriptsAffected":[{"name":"FLT3-001","id":"ENST00000241453"},{"name":"FLT3-201","id":"ENST00000380982"},{"name":"FLT3-002","id":"ENST00000380987"},{"name":"FLT3-202","id":"ENST00000537084"}],"functionalImpact":"Unknown"},{"geneAffectedId":"ENSG00000271026","geneAffectedSymbol":"KATNBL1P1","geneStrand":1,"aaMutation":"","type":"exon_variant","transcriptsAffected":[{"name":"KATNBL1P1-001","id":"ENST00000605192"}],"functionalImpact":"Unknown"}],"study":[],"external_db_ids":{"clinvar":null,"civic":null},"clinical_significance":{"clinvar":null},"clinical_evidence":{"civic":null},"advQuery":{"mutation":{"id":{"is":["MU90171725"]}}},"uiDonors":[{"term":"LMS-FR","count":9,"advQuery":{"mutation":{"id":{"is":["MU90171725"]}},"donor":{"projectId":{"is":["LMS-FR"]}}},"countTotal":67,"percentage":0.13432835820895522,"projectName":"Soft tissue cancer - Leiomyosarcoma"}]},{"id":"MU12284958","type":"single base substitution","chromosome":"13","start":28607989,"end":28607989,"mutation":"T>G","assemblyVersion":"GRCh37","referenceGenomeAllele":"T","testedDonorCount":928,"affectedDonorCountTotal":8,"affectedDonorCountFiltered":8,"affectedProjectCount":3,"consequences":[{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"intron_variant","transcriptsAffected":[{"name":"FLT3-001","id":"ENST00000241453"},{"name":"FLT3-201","id":"ENST00000380982"},{"name":"FLT3-002","id":"ENST00000380987"},{"name":"FLT3-202","id":"ENST00000537084"}],"functionalImpact":"Unknown"}],"study":[],"external_db_ids":{"clinvar":null,"civic":null},"clinical_significance":{"clinvar":null},"clinical_evidence":{"civic":null},"advQuery":{"mutation":{"id":{"is":["MU12284958"]}}},"uiDonors":[{"term":"COCA-CN","count":5,"advQuery":{"mutation":{"id":{"is":["MU12284958"]}},"donor":{"projectId":{"is":["COCA-CN"]}}},"countTotal":321,"percentage":0.01557632398753894,"projectName":"Colorectal Cancer - CN"},{"term":"LAML-KR","count":2,"advQuery":{"mutation":{"id":{"is":["MU12284958"]}},"donor":{"projectId":{"is":["LAML-KR"]}}},"countTotal":205,"percentage":0.00975609756097561,"projectName":"Acute Myeloid Leukemia - KR"},{"term":"LICA-CN","count":1,"advQuery":{"mutation":{"id":{"is":["MU12284958"]}},"donor":{"projectId":{"is":["LICA-CN"]}}},"countTotal":402,"percentage":0.0024875621890547263,"projectName":"Liver Cancer - CN"}]},{"id":"MU24013025","type":"single base substitution","chromosome":"13","start":28624294,"end":28624294,"mutation":"G>A","assemblyVersion":"GRCh37","referenceGenomeAllele":"G","testedDonorCount":1132,"affectedDonorCountTotal":8,"affectedDonorCountFiltered":8,"affectedProjectCount":3,"consequences":[{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"T227M","cdsMutation":"680C>T","type":"missense_variant","transcriptsAffected":[{"name":"FLT3-001","id":"ENST00000241453"},{"name":"FLT3-201","id":"ENST00000380982"},{"name":"FLT3-202","id":"ENST00000537084"}],"functionalImpact":"Low"},{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"exon_variant","transcriptsAffected":[{"name":"FLT3-002","id":"ENST00000380987"}],"functionalImpact":"Unknown"}],"study":[],"external_db_ids":{"clinvar":null,"civic":540},"description":"FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib.","clinical_significance":{"clinvar":null},"clinical_evidence":{"civic":[{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/540","clinicalImpact":"Adverse Response","rating":"3","doid":"4450","referenceBuild":"GRCh37","evidenceDirection":"Supports","chromosomeEnd":"28624294","evidenceID":"1317","variant":"T227M","lastViewDate":"2016-05-17 17:47:03 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/1317","entrezID":"2322","start2":"","chromosomeStart":"28624294","civicID":"540","disease":"Renal Cell Carcinoma","evidenceStatement":"In 219 patients with mostly Renal Cell Carcinoma and some Gastrointestinal Stromal tumors given sunitinib treatment, FLT3 T227M (rs1933437) was associated with the development of leukopenia. 95% confidence interval of hazard ratio of between .17 and .77.","gene":"FLT3","drugs":"Sunitinib","citation":"van Erp et al., 2009, J. Clin. Oncol.","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"19667267","representativeTranscript":"ENST00000241453.7","variantSummary":"FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib.","mutation":"G>A","geneID":"24","evidenceType":"Predictive","stop2":"","evidenceStatus":"accepted","evidenceLevel":"B - Clinical","variantOrigin":"Germline Polymorphism"}]},"uiClinicalEvidenceCounts":[0,1,0,0,0],"advQuery":{"mutation":{"id":{"is":["MU24013025"]}}},"uiDonors":[{"term":"COCA-CN","count":6,"advQuery":{"mutation":{"id":{"is":["MU24013025"]}},"donor":{"projectId":{"is":["COCA-CN"]}}},"countTotal":321,"percentage":0.018691588785046728,"projectName":"Colorectal Cancer - CN"},{"term":"ESAD-UK","count":1,"advQuery":{"mutation":{"id":{"is":["MU24013025"]}},"donor":{"projectId":{"is":["ESAD-UK"]}}},"countTotal":409,"percentage":0.0024449877750611247,"projectName":"Esophageal Adenocarcinoma - UK"},{"term":"LICA-CN","count":1,"advQuery":{"mutation":{"id":{"is":["MU24013025"]}},"donor":{"projectId":{"is":["LICA-CN"]}}},"countTotal":402,"percentage":0.0024875621890547263,"projectName":"Liver Cancer - CN"}]},{"id":"MU14977756","type":"single base substitution","chromosome":"13","start":28609846,"end":28609846,"mutation":"A>T","assemblyVersion":"GRCh37","referenceGenomeAllele":"A","testedDonorCount":526,"affectedDonorCountTotal":7,"affectedDonorCountFiltered":7,"affectedProjectCount":2,"consequences":[{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"intron_variant","transcriptsAffected":[{"name":"FLT3-001","id":"ENST00000241453"},{"name":"FLT3-201","id":"ENST00000380982"},{"name":"FLT3-002","id":"ENST00000380987"},{"name":"FLT3-202","id":"ENST00000537084"}],"functionalImpact":"Unknown"}],"study":[],"external_db_ids":{"clinvar":null,"civic":null},"clinical_significance":{"clinvar":null},"clinical_evidence":{"civic":null},"advQuery":{"mutation":{"id":{"is":["MU14977756"]}}},"uiDonors":[{"term":"COCA-CN","count":5,"advQuery":{"mutation":{"id":{"is":["MU14977756"]}},"donor":{"projectId":{"is":["COCA-CN"]}}},"countTotal":321,"percentage":0.01557632398753894,"projectName":"Colorectal Cancer - CN"},{"term":"LAML-KR","count":2,"advQuery":{"mutation":{"id":{"is":["MU14977756"]}},"donor":{"projectId":{"is":["LAML-KR"]}}},"countTotal":205,"percentage":0.00975609756097561,"projectName":"Acute Myeloid Leukemia - KR"}]},{"id":"MU114404460","type":"deletion of <=200bp","chromosome":"13","start":28623939,"end":28623939,"mutation":"A>-","assemblyVersion":"GRCh37","referenceGenomeAllele":"A","testedDonorCount":906,"affectedDonorCountTotal":7,"affectedDonorCountFiltered":7,"affectedProjectCount":2,"consequences":[{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"intron_variant","transcriptsAffected":[{"name":"FLT3-001","id":"ENST00000241453"},{"name":"FLT3-201","id":"ENST00000380982"},{"name":"FLT3-002","id":"ENST00000380987"},{"name":"FLT3-202","id":"ENST00000537084"}],"functionalImpact":"Unknown"}],"study":[],"external_db_ids":{"clinvar":null,"civic":null},"clinical_significance":{"clinvar":null},"clinical_evidence":{"civic":null},"advQuery":{"mutation":{"id":{"is":["MU114404460"]}}},"uiDonors":[{"term":"COCA-CN","count":2,"advQuery":{"mutation":{"id":{"is":["MU114404460"]}},"donor":{"projectId":{"is":["COCA-CN"]}}},"countTotal":321,"percentage":0.006230529595015576,"projectName":"Colorectal Cancer - CN"},{"term":"GACA-JP","count":5,"advQuery":{"mutation":{"id":{"is":["MU114404460"]}},"donor":{"projectId":{"is":["GACA-JP"]}}},"countTotal":585,"percentage":0.008547008547008548,"projectName":"Gastric Cancer - JP"}]},{"id":"MU14977712","type":"single base substitution","chromosome":"13","start":28609825,"end":28609825,"mutation":"A>G","assemblyVersion":"GRCh37","referenceGenomeAllele":"A","testedDonorCount":526,"affectedDonorCountTotal":7,"affectedDonorCountFiltered":7,"affectedProjectCount":2,"consequences":[{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"intron_variant","transcriptsAffected":[{"name":"FLT3-001","id":"ENST00000241453"},{"name":"FLT3-201","id":"ENST00000380982"},{"name":"FLT3-002","id":"ENST00000380987"},{"name":"FLT3-202","id":"ENST00000537084"}],"functionalImpact":"Unknown"}],"study":[],"external_db_ids":{"clinvar":null,"civic":null},"clinical_significance":{"clinvar":null},"clinical_evidence":{"civic":null},"advQuery":{"mutation":{"id":{"is":["MU14977712"]}}},"uiDonors":[{"term":"COCA-CN","count":5,"advQuery":{"mutation":{"id":{"is":["MU14977712"]}},"donor":{"projectId":{"is":["COCA-CN"]}}},"countTotal":321,"percentage":0.01557632398753894,"projectName":"Colorectal Cancer - CN"},{"term":"LAML-KR","count":2,"advQuery":{"mutation":{"id":{"is":["MU14977712"]}},"donor":{"projectId":{"is":["LAML-KR"]}}},"countTotal":205,"percentage":0.00975609756097561,"projectName":"Acute Myeloid Leukemia - KR"}]},{"id":"MU820458","type":"single base substitution","chromosome":"13","start":28592642,"end":28592642,"mutation":"C>A","assemblyVersion":"GRCh37","referenceGenomeAllele":"C","testedDonorCount":510,"affectedDonorCountTotal":7,"affectedDonorCountFiltered":7,"affectedProjectCount":3,"consequences":[{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"intron_variant","transcriptsAffected":[{"name":"FLT3-202","id":"ENST00000537084"}],"functionalImpact":"Unknown"},{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"D835Y","cdsMutation":"2503G>T","type":"missense_variant","transcriptsAffected":[{"name":"FLT3-001","id":"ENST00000241453"},{"name":"FLT3-201","id":"ENST00000380982"}],"functionalImpact":"High"},{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"upstream_gene_variant","transcriptsAffected":[{"name":"FLT3-003","id":"ENST00000469894"}],"functionalImpact":"Unknown"},{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"3_prime_UTR_variant","transcriptsAffected":[{"name":"FLT3-002","id":"ENST00000380987"}],"functionalImpact":"Unknown"}],"study":[],"external_db_ids":{"clinvar":16276,"civic":56},"description":"FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.","clinical_significance":{"clinvar":{"origin":"somatic","lastEvaluated":"Oct 02, 2014","chromosomeAccession":"NC_000013.10","cytogenetic":"13q12.2","variantType":"single nucleotide variant","chromosomeEnd":"28592642","originSimple":"somatic","rcVaccession":"RCV000017666;RCV000017665","assembly":"GRCh37","hgncID":"HGNC:3765","guidelines":"","otherIDs":"OMIM Allelic Variant:136351.0007,UniProtKB (protein):P36888#VAR_065683","rsNumber":"121913488","alternateAllele":"A","testedInGTR":"N","variationType":"Variant","chromosomeStart":"28592642","numberSubmitters":"2","chromosome":"13","geneSymbol":"FLT3","clinicalSignificance":"Pathogenic","mutation":"C>A","clinvarID":16276,"geneID":"2322","clinSigSimple":"1","nsvEsv":"-","alleleID":31315,"name":"NM_004119.2(FLT3):c.2503G>T (p.Asp835Tyr)","phenotypeList":"Acute lymphoid leukemia;Acute myeloid leukemia","submitterCategories":"1","referenceAllele":"C","reviewStatus":"no assertion criteria provided","phenotypeIDS":"MedGen:C0023449,OMIM:613065,Orphanet:ORPHA513,SNOMED CT:91857003;Human Phenotype Ontology:HP:0004808,MeSH:D015470,MedGen:C0023467,OMIM:601626,Orphanet:ORPHA519,SNOMED CT:17788007","interpreted":false}},"clinical_evidence":{"civic":[{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/56","clinicalImpact":"Better Outcome","rating":"3","doid":"9119","referenceBuild":"GRCh37","evidenceDirection":"Supports","chromosomeEnd":"28592642","evidenceID":"171","variant":"TKD MUTATION","lastViewDate":"2016-03-16 22:09:27 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/171","entrezID":"2322","start2":"","chromosomeStart":"28592642","civicID":"56","disease":"Acute Myeloid Leukemia","evidenceStatement":"Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis 3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal karyotype patients were analyzed.","gene":"FLT3","drugs":"","citation":"Bacher et al., 2008, Blood","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"17965322","representativeTranscript":"ENST00000241453.7","variantSummary":"FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.","mutation":"C>A","geneID":"24","evidenceType":"Prognostic","stop2":"","evidenceStatus":"accepted","evidenceLevel":"B - Clinical","variantOrigin":"Somatic Mutation"},{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/56","clinicalImpact":"Positive","rating":"3","doid":"9119","referenceBuild":"GRCh37","evidenceDirection":"Does Not Support","chromosomeEnd":"28592642","evidenceID":"214","variant":"TKD MUTATION","lastViewDate":"2016-03-16 22:09:27 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/214","entrezID":"2322","start2":"","chromosomeStart":"28592642","civicID":"56","disease":"Acute Myeloid Leukemia","evidenceStatement":"WBC counts were not significantly different in AML patients with FLT3 D835 mutations compared to wild type.","gene":"FLT3","drugs":"","citation":"Yamamoto et al., 2001, Blood","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"11290608","representativeTranscript":"ENST00000241453.7","variantSummary":"FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.","mutation":"C>A","geneID":"24","evidenceType":"Diagnostic","stop2":"","evidenceStatus":"accepted","evidenceLevel":"B - Clinical","variantOrigin":"Somatic Mutation"},{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/56","clinicalImpact":"Resistance","rating":"4","doid":"9119","referenceBuild":"GRCh37","evidenceDirection":"Supports","chromosomeEnd":"28592642","evidenceID":"247","variant":"TKD MUTATION","lastViewDate":"2016-03-16 22:09:26 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/247","entrezID":"2322","start2":"","chromosomeStart":"28592642","civicID":"56","disease":"Acute Myeloid Leukemia","evidenceStatement":"Emergence of D835 mutation in AML patients with FLT3 tandem repeat is associated with sorafenib resistance.","gene":"FLT3","drugs":"Sorafenib","citation":"Man et al., 2012, Blood","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"22368270","representativeTranscript":"ENST00000241453.7","variantSummary":"FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.","mutation":"C>A","geneID":"24","evidenceType":"Predictive","stop2":"","evidenceStatus":"accepted","evidenceLevel":"B - Clinical","variantOrigin":"Somatic Mutation"},{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/56","clinicalImpact":"Resistance","rating":"4","doid":"9119","referenceBuild":"GRCh37","evidenceDirection":"Supports","chromosomeEnd":"28592642","evidenceID":"248","variant":"TKD MUTATION","lastViewDate":"2015-06-21 16:49:48 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/248","entrezID":"2322","start2":"","chromosomeStart":"28592642","civicID":"56","disease":"Acute Myeloid Leukemia","evidenceStatement":"Sorafenib is effective in patients with FLT3 internal tandem repeat mutations, but not in patients with wild type or D835 mutation.","gene":"FLT3","drugs":"Sorafenib","citation":"Zhang et al., 2008, J. Natl. Cancer Inst.","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"18230792","representativeTranscript":"ENST00000241453.7","variantSummary":"FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.","mutation":"C>A","geneID":"24","evidenceType":"Predictive","stop2":"","evidenceStatus":"accepted","evidenceLevel":"B - Clinical","variantOrigin":"Somatic Mutation"},{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/56","clinicalImpact":"N/A","rating":"3","doid":"9119","referenceBuild":"GRCh37","evidenceDirection":"Does Not Support","chromosomeEnd":"28592642","evidenceID":"322","variant":"TKD MUTATION","lastViewDate":"2016-03-16 22:09:26 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/322","entrezID":"2322","start2":"","chromosomeStart":"28592642","civicID":"56","disease":"Acute Myeloid Leukemia","evidenceStatement":"AML patients with D835 mutation of FLT3 did not have worse overall survival than patients with wild type FLT3.","gene":"FLT3","drugs":"","citation":"Yamamoto et al., 2001, Blood","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"11290608","representativeTranscript":"ENST00000241453.7","variantSummary":"FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.","mutation":"C>A","geneID":"24","evidenceType":"Prognostic","stop2":"","evidenceStatus":"accepted","evidenceLevel":"B - Clinical","variantOrigin":"Somatic Mutation"},{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/56","clinicalImpact":"Poor Outcome","rating":"4","doid":"9119","referenceBuild":"GRCh37","evidenceDirection":"Supports","chromosomeEnd":"28592642","evidenceID":"373","variant":"TKD MUTATION","lastViewDate":"2016-03-16 22:09:26 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/373","entrezID":"2322","start2":"","chromosomeStart":"28592642","civicID":"56","disease":"Acute Myeloid Leukemia","evidenceStatement":"In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3.","gene":"FLT3","drugs":"","citation":"Whitman et al., 2008, Blood","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"17940205","representativeTranscript":"ENST00000241453.7","variantSummary":"FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.","mutation":"C>A","geneID":"24","evidenceType":"Prognostic","stop2":"","evidenceStatus":"accepted","evidenceLevel":"B - Clinical","variantOrigin":"Somatic Mutation"},{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/437","clinicalImpact":"Resistance","rating":"3","doid":"9119","referenceBuild":"GRCh37","evidenceDirection":"Supports","chromosomeEnd":"28592642","evidenceID":"1036","variant":"D835","lastViewDate":"2016-02-21 22:23:23 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/1036","entrezID":"2322","start2":"","chromosomeStart":"28592642","civicID":"437","disease":"Acute Myeloid Leukemia","evidenceStatement":"An in-vitro saturation mutagenesis screen of 50 independently derived FLT3-ITD clones was performed to identify mutations that confer resistance to ponatinib. Mutations at 3 AL residues (D835 [n = 31], D839 [n = 3], and Y842 [n = 16]), with varying degrees of resistance to ponatinib were identified. FLT3 D835 mutations were shown to confer resistance to the tyrosine kinase inhibitor AC220 and ponatinib.  This was especially found for D835Y and D835V mutations, whereas D835H mutations were found to confer moderate resistance to ponatinib but relatively minimal resistance to AC220.","gene":"FLT3","drugs":"Quizartinib (AC220),Ponatinib","citation":"Smith et al., 2013, Blood","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"23430109","representativeTranscript":"ENST00000241453.7","variantSummary":"","mutation":"C>A","geneID":"24","evidenceType":"Predictive","stop2":"","evidenceStatus":"accepted","evidenceLevel":"D - Preclinical","variantOrigin":"Somatic Mutation"},{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/437","clinicalImpact":"Resistance","rating":"3","doid":"9119","referenceBuild":"GRCh37","evidenceDirection":"Supports","chromosomeEnd":"28592642","evidenceID":"1037","variant":"D835","lastViewDate":"2016-02-22 02:47:15 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/1037","entrezID":"2322","start2":"","chromosomeStart":"28592642","civicID":"437","disease":"Acute Myeloid Leukemia","evidenceStatement":"An in-vitro cell-based screening approach generated FLT3-ITD-expressing cell lines resistant to the FLT3 inhibitors SU5614, PKC412, and sorafenib. SU5614 resistance mutations were limited to exchanges in the second part of the kinase domain (TK2), with exchanges of D835 predominating (D835E were most common). In clones that emerged at 1,500 nmol/L SU5614 after ENU (mutagen) treatment, 127 of 179 clones (71%) displayed mutations, generating 9 different exchanges affecting 6 positions in the activation loop of FLT3.","gene":"FLT3","drugs":"SU5614","citation":"von Bubnoff et al., 2009, Cancer Res.","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"19318574","representativeTranscript":"ENST00000241453.7","variantSummary":"","mutation":"C>A","geneID":"24","evidenceType":"Predictive","stop2":"","evidenceStatus":"accepted","evidenceLevel":"D - Preclinical","variantOrigin":"Somatic Mutation"},{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/437","clinicalImpact":"Resistance","rating":"4","doid":"9119","referenceBuild":"GRCh37","evidenceDirection":"Supports","chromosomeEnd":"28592642","evidenceID":"1038","variant":"D835","lastViewDate":"2016-07-13 23:40:36 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/1038","entrezID":"2322","start2":"","chromosomeStart":"28592642","civicID":"437","disease":"Acute Myeloid Leukemia","evidenceStatement":"In an in-vitro study using an in vitro saturation mutagenesis assay, 4 residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. Mutations at three of these amino acid positions conferred high degrees of in vitro AC220 resistance (based on proliferation and cell-based biochemical assays). Among these residues, two within the activation loop were found (D835, Y842).  Pre-treatment and relapse samples of 8 patients (treated with AC220) with FLT3-ITD+ acute myeloid leukemia were analyzed. The activation loop mutation D835Y was detected in three cases, D835V in two, and D835F was identified in a single patient. Cross-resistance to sorafenib was identified in-vitro.","gene":"FLT3","drugs":"Quizartinib (AC220),Sorafenib","citation":"Smith et al., 2012, Nature","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"22504184","representativeTranscript":"ENST00000241453.7","variantSummary":"","mutation":"C>A","geneID":"24","evidenceType":"Predictive","stop2":"","evidenceStatus":"accepted","evidenceLevel":"B - Clinical","variantOrigin":"Somatic Mutation"},{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/437","clinicalImpact":"Resistance","rating":"4","doid":"9119","referenceBuild":"GRCh37","evidenceDirection":"Supports","chromosomeEnd":"28592642","evidenceID":"1039","variant":"D835","lastViewDate":"2016-02-19 23:15:01 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/1039","entrezID":"2322","start2":"","chromosomeStart":"28592642","civicID":"437","disease":"Acute Myeloid Leukemia","evidenceStatement":"13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients responded, but sorafenib response was lost in most patients after 72 (range 54-287) days. Leukemia initiating cells bearing the D835 mutation expanded during sorafenib treatment and dominated during the subsequent clinical resistance. Results were recapitulated in-vivo.","gene":"FLT3","drugs":"Sorafenib","citation":"Man et al., 2012, Blood","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"22368270","representativeTranscript":"ENST00000241453.7","variantSummary":"","mutation":"C>A","geneID":"24","evidenceType":"Predictive","stop2":"","evidenceStatus":"accepted","evidenceLevel":"B - Clinical","variantOrigin":"Somatic Mutation"},{"variantCivicUrl":"https://civic.genome.wustl.edu/links/variants/56","clinicalImpact":"Sensitivity/Response","rating":"3","doid":"9119","referenceBuild":"GRCh37","evidenceDirection":"Supports","chromosomeEnd":"28592642","evidenceID":"1295","variant":"TKD MUTATION","lastViewDate":"2016-10-25 04:27:24 UTC","evidenceCivicUrl":"https://civic.genome.wustl.edu/links/evidence_items/1295","entrezID":"2322","start2":"","chromosomeStart":"28592642","civicID":"56","disease":"Acute Myeloid Leukemia","evidenceStatement":"In a phase 2 clinical study of 95 AML/high-risk MDS patients treated with either 50 or 100 mg midostaurin, 35 harbored FLT3 mutations (26 had FLT3 ITD, 9 had FLT3 D835Y mutations). A higher percentage of patients saw blast reductions in the FLT3 mutant group than in the FLT3 wild type group (71 vs 42%). Only one permanent response occurred in a FLT3 mutant patient receiving the 100 mg dose. No differences were observed in toxicity or response rate between the two doses of midostaurin.","gene":"FLT3","drugs":"Midostaurin","citation":"Fischer et al., 2010, J. Clin. Oncol.","ensemblVersion":"75","chromosome2":"","chromosome":"13","geneCivicUrl":"https://civic.genome.wustl.edu/links/genes/24","representativeTranscript2":"","pubmedID":"20733134","representativeTranscript":"ENST00000241453.7","variantSummary":"FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.","mutation":"C>A","geneID":"24","evidenceType":"Predictive","stop2":"","evidenceStatus":"accepted","evidenceLevel":"B - Clinical","variantOrigin":"Somatic Mutation"}]},"uiClinicalEvidenceCounts":[0,9,0,2,0],"advQuery":{"mutation":{"id":{"is":["MU820458"]}}},"uiDonors":[{"term":"AML-US","count":1,"advQuery":{"mutation":{"id":{"is":["MU820458"]}},"donor":{"projectId":{"is":["AML-US"]}}},"countTotal":166,"percentage":0.006024096385542169,"projectName":"Acute Myeloid Leukemia - TARGET, US"},{"term":"LAML-KR","count":5,"advQuery":{"mutation":{"id":{"is":["MU820458"]}},"donor":{"projectId":{"is":["LAML-KR"]}}},"countTotal":205,"percentage":0.024390243902439025,"projectName":"Acute Myeloid Leukemia - KR"},{"term":"LAML-US","count":1,"advQuery":{"mutation":{"id":{"is":["MU820458"]}},"donor":{"projectId":{"is":["LAML-US"]}}},"countTotal":139,"percentage":0.007194244604316547,"projectName":"Acute Myeloid Leukemia - TCGA, US"}]},{"id":"MU51654062","type":"single base substitution","chromosome":"13","start":28585122,"end":28585122,"mutation":"G>A","assemblyVersion":"GRCh37","referenceGenomeAllele":"G","testedDonorCount":1109,"affectedDonorCountTotal":6,"affectedDonorCountFiltered":6,"affectedProjectCount":5,"consequences":[{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"intron_variant","transcriptsAffected":[{"name":"FLT3-001","id":"ENST00000241453"},{"name":"FLT3-201","id":"ENST00000380982"},{"name":"FLT3-002","id":"ENST00000380987"},{"name":"FLT3-003","id":"ENST00000469894"},{"name":"FLT3-202","id":"ENST00000537084"}],"functionalImpact":"Unknown"}],"study":[],"external_db_ids":{"clinvar":null,"civic":null},"clinical_significance":{"clinvar":null},"clinical_evidence":{"civic":null},"advQuery":{"mutation":{"id":{"is":["MU51654062"]}}},"uiDonors":[{"term":"EOPC-DE","count":2,"advQuery":{"mutation":{"id":{"is":["MU51654062"]}},"donor":{"projectId":{"is":["EOPC-DE"]}}},"countTotal":202,"percentage":0.009900990099009901,"projectName":"Early Onset Prostate Cancer - DE"},{"term":"ESAD-UK","count":1,"advQuery":{"mutation":{"id":{"is":["MU51654062"]}},"donor":{"projectId":{"is":["ESAD-UK"]}}},"countTotal":409,"percentage":0.0024449877750611247,"projectName":"Esophageal Adenocarcinoma - UK"},{"term":"GACA-CN","count":1,"advQuery":{"mutation":{"id":{"is":["MU51654062"]}},"donor":{"projectId":{"is":["GACA-CN"]}}},"countTotal":123,"percentage":0.008130081300813009,"projectName":"Gastric Cancer - CN"},{"term":"LAML-KR","count":1,"advQuery":{"mutation":{"id":{"is":["MU51654062"]}},"donor":{"projectId":{"is":["LAML-KR"]}}},"countTotal":205,"percentage":0.004878048780487805,"projectName":"Acute Myeloid Leukemia - KR"},{"term":"LUSC-KR","count":1,"advQuery":{"mutation":{"id":{"is":["MU51654062"]}},"donor":{"projectId":{"is":["LUSC-KR"]}}},"countTotal":170,"percentage":0.0058823529411764705,"projectName":"Lung Cancer - KR"}]},{"id":"MU657113","type":"single base substitution","chromosome":"13","start":28602256,"end":28602256,"mutation":"C>T","assemblyVersion":"GRCh37","referenceGenomeAllele":"C","testedDonorCount":827,"affectedDonorCountTotal":6,"affectedDonorCountFiltered":6,"affectedProjectCount":4,"consequences":[{"geneAffectedId":"ENSG00000122025","geneAffectedSymbol":"FLT3","geneStrand":-1,"aaMutation":"","type":"intron_variant","transcriptsAffected":[{"name":"FLT3-001","id":"ENST00000241453"},{"name":"FLT3-201","id":"ENST00000380982"},{"name":"FLT3-002","id":"ENST00000380987"},{"name":"FLT3-202","id":"ENST00000537084"}],"functionalImpact":"Unknown"}],"study":[],"external_db_ids":{"clinvar":null,"civic":null},"clinical_significance":{"clinvar":null},"clinical_evidence":{"civic":null},"advQuery":{"mutation":{"id":{"is":["MU657113"]}}},"uiDonors":[{"term":"BRCA-KR","count":1,"advQuery":{"mutation":{"id":{"is":["MU657113"]}},"donor":{"projectId":{"is":["BRCA-KR"]}}},"countTotal":50,"percentage":0.02,"projectName":"Breast Cancer - Very young women"},{"term":"LAML-KR","count":1,"advQuery":{"mutation":{"id":{"is":["MU657113"]}},"donor":{"projectId":{"is":["LAML-KR"]}}},"countTotal":205,"percentage":0.004878048780487805,"projectName":"Acute Myeloid Leukemia - KR"},{"term":"LICA-CN","count":2,"advQuery":{"mutation":{"id":{"is":["MU657113"]}},"donor":{"projectId":{"is":["LICA-CN"]}}},"countTotal":402,"percentage":0.004975124378109453,"projectName":"Liver Cancer - CN"},{"term":"LUSC-KR","count":2,"advQuery":{"mutation":{"id":{"is":["MU657113"]}},"donor":{"projectId":{"is":["LUSC-KR"]}}},"countTotal":170,"percentage":0.011764705882352941,"projectName":"Lung Cancer - KR"}]}]